Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Genetic toxicity: in vivo

Currently viewing:

Administrative data

Endpoint:
in vivo mammalian germ cell study: cytogenicity / chromosome aberration
Remarks:
Type of genotoxicity: chromosome aberration
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: Limited documentation of study methods (purity of test substance not given).

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
1972
Report date:
1972

Materials and methods

Principles of method if other than guideline:
Rodent Dominant Lethal Test.
GLP compliance:
no
Type of assay:
rodent dominant lethal assay

Test material

Constituent 1
Chemical structure
Reference substance name:
D-glucitol
EC Number:
200-061-5
EC Name:
D-glucitol
Cas Number:
50-70-4
Molecular formula:
C6H14O6
IUPAC Name:
D-glucitol
Details on test material:
- Name of test material (as cited in study report): sorbitol, FDA 71-31

Test animals

Species:
rat
Sex:
male/female

Administration / exposure

Route of administration:
oral: gavage
Duration of treatment / exposure:
Acute-single dose procedure: once a week over 8 weeks, no further details given
Subacute-multipe dose procedure: 7 weeks
Doses / concentrations
Remarks:
Doses / Concentrations:
2500, 5000, 30000 mg/kg bw
Basis:
actual ingested
No. of animals per sex per dose:
Varying between 16 and 20, depending on dose group and treatment week (no further details given).
Control animals:
yes
Positive control(s):
triethylenemelamine (TEM)
- Doses / concentrations: 0.2 mg/kg bw

Results and discussion

Test results
Sex:
male/female
Genotoxicity:
negative
Toxicity:
not specified
Negative controls validity:
valid
Positive controls validity:
valid

Any other information on results incl. tables

Table 1: Average implantations per pregnant female

Week of study

Control

TEM

2500 mg/kg bw

5000 mg/kg bw

30000 mg/kg bw

Acute-Single Dose

1

236/19=12.4

193/19=10.2*

214/17=12.6

234/19=12.3

197/16=12.3

2

220/20=11

159/19=8.4*

250/20=12.5

227/19=11.9

234/20=11.7

3

209/20=10.5

170/20=8.5

254/20=12.7**I

210/18=11.7

212/20=10.6

4

230/20=11.5

60/18=3.3*

239/20=12

213/19=11.2

199/20=10

5

214/20=10.7

191/19=10.1

231/20=11.6

202/16=12.6**I

267/20=13.4**I

6

236/20=11.8

227/20=11.4

234/20=11.7

235/20=11.8

222/20=11.1

7

239/20=12

230/20=11.5

240/20=12

238/20=11.9

236/20=11.8

8

224/20=11.2

213/20=10.7

164/16=10.3

219/20=11.5

252/20=12.6*I

Subacute-Multiple Dose

1

 

 

215/17=12.6

207/18=11.5

242/19=12.7

2

 

 

190/19=10

224/20=11.2

195/17=11.5

3

 

 

236/20=11.8

239/20=12

209/20=10.5

4

 

 

236/20=11.8

211/17=12.4

247/20=12.4

5

 

 

254/19=13.4**I

255/20=12.8**I

236/18=13.1**I

6

 

 

246/20=12.3

186/19=9.8

191/17=11.2

7

 

 

212/18=11.8

237/19=12.5

215/20=10.8

* significant at p<0.05

** significant at p<0.01

I increase above control

Table 2: Average dead implants per pregnant female

Week of study

Control

TEM

2500 mg/kg bw

5000 mg/kg bw

30000 mg/kg bw

Acute-Single Dose

1

18/19=0.95

75/19=3.95**

18/17=1.06

8/19=0.42

20/16=1.25

2

11/20=0.55

135/19=7.11**

6/20=0.3

11/19=0.58

11/20=0.55

3

18/20=0.9

144/20=7.2**

19/20=0.95

7/18=0.39

17/20=0.85

4

19/20=0.95

58/18=3.22**

29/20=1.45

17/19=0.89

15/20=0.75

5

15/20=0.75

62/19=3.26**

18/20=0.9

5/16=0.31

12/20=0.6

6

22/20=1.10

41/20=2.05*

9/20=0.45*D

11/20=0.55

16/20=0.8

7

24/20=1.2

26/20=1.3

12/20=0.6

15/20=0.75

24/20=1.2

8

11/20=0.55

18/20=0.9

17/16=1.06

11/19=0.58

28/16=1.4

Subacute-Multiple Dose

1

 

 

9/17=0.53

20/18=1.11

12/19=0.63

2

 

 

15/19=0.79

11/20=0.55

11/17=0.65

3

 

 

14/20=0.70

15/20=0.75

13/20=0.65

4

 

 

6/20=0.3

26/17=1.53

24/20=1.2

5

 

 

11/19=0.58

25/20=1.25

17/18=0.94

6

 

 

13/20=0.65

8/19=0.42

19/17=1.12

7

 

 

11/18=0.61

11/19=0.58

20/20=1

* significant at p<0.05

** significant at p<0.01

D decrease below control

Table 3: Dead implants/total implants

Week of study

Control

TEM

2500 mg/kg bw

5000 mg/kg bw

30000 mg/kg bw

Acute-Single Dose

1

18/236=0.08

75/193=0.39**

18/214=0.08

8/234=0.03

20/197=0.1

2

11/220=0.05

135/159=0.85**

6/250=0.02*D

11/227=0.05

11/234=0.05

3

18/209=0.09

144/170=0.85**

19/254=0.07

7/210=0.03

17/212=0.08

4

19/230=0.08

58/60=0.97**

29/239=0.12

17/213=0.08

15/199=0.08

5

15/214=0.07

62/191=0.32**

18/231=0.08

5/202=0.02

12/267=0.04

6

22/236=0.09

41/227=0.18

9/234=0.04

11/235=0.05

16/222=0.07

7

24/239=0.10

26/230=0.11

12/240=0.05

15/238=0.6

24/236=0.10

8

11/224=0.05

18/213=0.08

17/164=0.1*

11/219=0.05

28/252=0.11

Subacute-Multiple Dose

1

 

 

9/215=0.04

20/207=0.1

12/242=0.05

2

 

 

15/190=0.08

11/224=0.05

11/195=0.06

3

 

 

14/236=0.06

15/239=0.06

13/209=0.06

4

 

 

6/236=0.03

26/211=0.12

24/247=0.10

5

 

 

11/254=0.04

25/255=0.1

17/236=0.07

6

 

 

13/246=0.05

8/186=0.04

19/191=0.10

7

 

 

11/212=0.05

11/237=0.05

20/215=0.09

* significant at p<0.05

** significant at p<0.01

D decrease below control

Table 4: Average corpora lutea per pregnant female

Week of study

Control

TEM

2500 mg/kg bw

5000 mg/kg bw

30000 mg/kg bw

Acute-Single Dose

1

252/19=13.3

252/19=13.3

233/17=13.7

257/19=13.5

216/16=13.5

2

254/20=12.7

220/19=11.6

278/20=13.9

244/19=12.8

257/20=12.9

3

244/20=12.2

247/20=12.4

271/20=13.6*I

230/18=12.2

264/20=13.2

4

260/20=13

227/18=12.6

267/20=13.4

250/19=13.2

237/20=11.9

5

244/20=12.2

234/19=12.3

252/20=12.6

210/16=13.1*I

277/20=13.9*I

6

265/20=13.3

253/20=12.7

270/20=13.5

253/20=12.7

247/20=12.4

7

259/20=13

250/20=12.5

271/20=13.6

267/20=13.4

248/20=12.4

8

242/20=12.1

258/20=12.9

203/16=12.7

237/19=12.5

260/20=13

Subacute-Multiple Dose

1

 

 

235/17=13.8

235/18=13.1

250/19=13.2

2

 

 

251/19=13.2

260/20=13

210/17=12.4

3

 

 

265/20=13.3

269/20=13.5*I

243/20=12.2

4

 

 

266/20=13.3

226/17=13.3

278/20=13.9

5

 

 

280/19=14.7**I

268/20=13.4*I

247/18=13.7**I

6

 

 

262/20=13.1

225/19=11.8*

206/17=12.1*

7

 

 

236/18=13.1

243/19=12.8

257/20=12.9

* significant at p<0.05

** significant at p<0.01

I increase above control

Table 5: Average preimplantation loss per pregnant female

Week of study

Control

TEM

2500 mg/kg bw

5000 mg/kg bw

30000 mg/kg bw

Acute-Single Dose

1

16/19=0.84

59/19=3.11*

19/17=1.12

23/19=1.21

19/16=1.19

2

34/20=1.7

61/19=3.21*

28/20=1.4

17/19=0.89

23/20=1.15

3

35/20=1.75

77/20=3.85*

17/20=0.85

20/18=1.11

52/20=2.6

4

30/20=1.5

167/18=9.28**

28/20=1.4

37/19=1.95

38/20=1.9

5

30/20=1.5

43/19=2.26

21/20=1.05

8/16=0.5

10/20=0.5*D

6

29/20=1.45

26/20=1.30

36/20=1.80

18/20=0.9

25/20=1.25

7

20/20=1

20/20=1

31/20=1.55

29/20=1.45

12/20=0.6

8

18/20=0.9

45/20=2.25

39/16=2.44

18/19=0.95

8/20=0.4

Subacute-Multiple Dose

1

 

 

20/17=1.18

28/18=1.56

8/19=0.42

2

 

 

61/19=3.21

36/20=1.8

15/17=0.88

3

 

 

29/20=1.45

30/20=1.5

34/20=1.7

4

 

 

30/20=1.50

15/17=0.88

31/20=1.55

5

 

 

26/19=1.37

13/20=0.65

11/18=0.61

6

 

 

16/20=0.8

39/19=2.05

15/17=0.88

7

 

 

24/18=1.33

6/19=0.32

42/20=2.1

* significant at p<0.05

** significant at p<0.01

D decrease below control

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): negative